Biomarker
|
Group
|
N
1
|
AUC
|
---|
| | |
CA/no CA
2
|
CA/benign
2
|
Abnormal/benign
2
|
---|
uPA+PAI-1
|
All
|
79
|
.72
|
.75
|
.74
|
uPA3
|
Pre
|
38
|
.87
|
.83
|
.86
|
TF4
|
Post
|
72
|
.81
|
.83
|
.83
|
TF+uPA
|
All
|
35
|
.84
|
.92
|
.91
|
TF+uPA+PAI-1
|
All
|
24
|
1.0
|
1.0
|
.97
|
-
1AUC: area under the receiver operating curve; uPA: urinary plasminogen activator; PAI (uPA inhibitor)-1, TF: Thomsen-Friedenreich antigen; N = number or sample size. The equivalent values as percent should be multiplied by 100 (i.e., .97 = 97%, and so forth)
-
2Cancer = ductal carcinoma in situ (DCIS), and invasive cancer; Benign = normal and hyperplasia; Abnormal = atypical hyperplasia, DCIS, and invasive cancer. Age is in all three models
-
3AUC values for postmenopausal women were lower
-
4previously published data [9]